Peptide-Based Immunodiagnostics for Divergent EIAV Strains
Solution Overview
Problem
Current diagnostic methods for equine infectious anemia (EIA) are inadequate in detecting divergent EIAV strains, leading to false negatives and inefficiencies in identifying infected horses, as they rely on whole virus or p26 recombinant proteins, which do not account for all serums of infected animals.
Innovation Solution
The use of specific peptides identified by mass spectrometry from EIAV seropositive horses, obtained from viral supernatants of macrophage cell cultures, for peptide-based immunodiagnostics that can detect divergent EIAV and NEV strains with similar sensitivity and specificity to immunoblot techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If whole virus or p26 recombinant proteins are used as antigens in current diagnostic methods, then the diagnostic test can be performed with available reagents, but the detection sensitivity is insufficient for divergent EIAV strains leading to false negatives
Solution Approach 1:
The patent segments the viral antigens into specific peptides (e.g., peptides of 10-50 amino acids from envelope proteins gp90 and gp45) rather than using whole virus or large recombinant proteins. This segmentation allows the diagnostic test to target specific epitopes that are conserved across divergent EIAV strains, thereby improving detection sensitivity and reducing false negatives while maintaining assay feasibility
Solution Approach 2:
The patent changes the physical and chemical parameters of the antigen by using synthetic peptides with specific molecular weights and sequences rather than whole virus particles. This parameter change enables the antigens to be more stable, easier to standardize, and capable of eliciting detectable antibody responses across different viral strains, thus improving both sensitivity and reliability
2Adaptability or versatility
If current immunodiagnostic tests use whole virus or p26 recombinant proteins, then the test methodology is established and standardized, but the tests fail to detect all seropositive subjects infected with divergent viral strains
Solution Approach 1:
The patent develops peptide antigens that serve multiple functions: they can detect antibodies against diverse EIAV strains (including divergent ones), they are stable across different storage conditions, and they can be used in various immunodiagnostic formats (ELISA, Western blot). This universality allows a single peptide-based antigen to replace multiple strain-specific antigens, improving both adaptability and detection accuracy
Solution Approach 2:
The patent creates synthetic peptide copies of specific viral epitopes rather than using the actual whole virus or large protein structures. These peptide copies replicate the essential antigenic determinants that elicit antibody responses, allowing detection of divergent strains while maintaining standardized, reproducible diagnostic conditions across different laboratories and test batches
Data Source
Figure 1
Figure 2~2.D2
Figure 3A
AI summary
A composition comprising one or more peptides selected from the group consisting of SEQ ID NOs 1 to 76; and/or comprising one or more polynucleotide sequences encoding one or more of the peptides selected from the group consisting of SEQ ID NOs 1 to 76;and/or comprising one or more polynucleotide sequences selected from the group consisting of SEQ ID NOs 77 to 152.